PMID- 17613433
OWN - NLM
STAT- MEDLINE
DCOM- 20070911
LR  - 20220410
IS  - 1535-6108 (Print)
IS  - 1535-6108 (Linking)
VI  - 12
IP  - 1
DP  - 2007 Jul
TI  - Defining the role of mTOR in cancer.
PG  - 9-22
AB  - The mammalian target of rapamycin (mTOR) has emerged as a critical effector in 
      cell-signaling pathways commonly deregulated in human cancers. This has led to 
      the prediction that mTOR inhibitors may be useful in oncology, and derivatives of 
      one such molecule, rapamycin (from which mTOR derives its name), are currently in 
      clinical development. In this review, we discuss recent progress in understanding 
      mTOR signaling, paying particular attention to its relevance in cancer. We 
      further discuss the use of rapamycin in oncology and conclude with a discussion 
      on the future of mTOR-targeted therapy.
FAU - Guertin, David A
AU  - Guertin DA
AD  - Whitehead Institute for Biomedical Research and Massachusetts Institute of 
      Technology, Department of Biology, Cambridge, MA 02141, USA.
FAU - Sabatini, David M
AU  - Sabatini DM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Humans
MH  - Neoplasms/drug therapy/metabolism/*physiopathology
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Protein Kinases/drug effects/*physiology
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases
RF  - 138
EDAT- 2007/07/07 09:00
MHDA- 2007/09/12 09:00
CRDT- 2007/07/07 09:00
PHST- 2007/02/12 00:00 [received]
PHST- 2007/04/10 00:00 [revised]
PHST- 2007/05/18 00:00 [accepted]
PHST- 2007/07/07 09:00 [pubmed]
PHST- 2007/09/12 09:00 [medline]
PHST- 2007/07/07 09:00 [entrez]
AID - S1535-6108(07)00151-1 [pii]
AID - 10.1016/j.ccr.2007.05.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2007 Jul;12(1):9-22. doi: 10.1016/j.ccr.2007.05.008.